Morgan Stanley Synlogic, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.42 - $0.68 $277,452 - $449,208	-660,600 Reduced 97.22%	18,902 $8,000
Q1 2023 May 15, 2023	SELL	$0.56 - $1.07 $430 - $821	-768 Reduced 0.11%	679,502 $428,000
Q4 2022 Feb 14, 2023	BUY	$0.58 - $17.99 $359 - $11,153	620 Added 0.09%	680,270 $517,000
Q3 2022 Nov 14, 2022	BUY	$0.91 - $14.63 $590,371 - $9.49 Million	648,760 Added 2100.23%	679,650 $646,000
Q2 2022 Oct 27, 2022	SELL	$0.89 - $2.47 $5,021 - $13,935	-5,642 Reduced 15.44%	30,890 $35,000
Q2 2022 Aug 15, 2022	SELL	$0.89 - $2.47 $5,021 - $13,935	-5,642 Reduced 15.44%	30,890 $35,000
Q1 2022 Oct 27, 2022	BUY	$1.63 - $2.55 $9,196 - $14,387	5,642 Added 18.26%	36,532 $87,000
Q1 2022 May 13, 2022	SELL	$1.63 - $2.55 $21,793 - $34,093	-13,370 Reduced 26.79%	36,532 $87,000
Q4 2021 Feb 14, 2022	SELL	$2.27 - $3.0 $59,598 - $78,765	-26,255 Reduced 34.47%	49,902 $121,000
Q3 2021 Nov 15, 2021	BUY	$2.45 - $4.1 $186,584 - $312,243	76,157 New	76,157 $232,000

25.5K

Ticker SYBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,229,600
Market Cap $103M
Description
Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotic medicines to treat metabolic and immunological diseases in the United States. Its therapeutic programs include SYNB1618 and SYNB1934 that are orally administered, non-systemically absorbed drug candidates, which are in Phase I...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.